P343 Efficacy of adalimumab in mild-to-moderate inflammatory bowel disease: Real-life data from single-centre experience in the long-term period
ECCO'20 Vienna
2020
P344 Effectiveness of ustekinumab in refractory Crohn’s disease: A real-life experience in a tertiary referral centre
ECCO'20 Vienna
2020
P345 Lack of anti-TNF drugs levels in fistula tissue: A reason for non-response in Crohn’s perianal fistula?
ECCO'20 Vienna
2020
P346 Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn’s disease patients
ECCO'20 Vienna
2020
P347 Undetectable levels of adalimumab in clinical practice: Should we say goodbye to the drug?
ECCO'20 Vienna
2020
P348 Clinical outcomes and response predictors of vedolizumab treatment for anti-TNF-failed patients with IBD in Korea: A prospective multicenter cohort study
ECCO'20 Vienna
2020
P350 Perceptions of faecal microbiota transplantation in patients with ulcerative colitis
ECCO'20 Vienna
2020
P351 Spontaneous intra-abdominal abscesses in Crohn’s disease: The experience of a tertiary centre
ECCO'20 Vienna
2020
P352 Infliximab-therapy intensification based on endoscopic activity suppresses treatment interruption among patients with Crohn’s disease
ECCO'20 Vienna
2020
P353 Assessing compliance to screening for infectious diseases and vaccination in patients newly diagnosed with inflammatory bowel disease
ECCO'20 Vienna
2020
P355 Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)
ECCO'20 Vienna
2020
P356 Infectious events in patients with inflammatory bowel disease: The impact of immunomodulators and tumour necrosis factor antagonist therapy
ECCO'20 Vienna
2020
P358 Predictors of response to faecal microbiota transplantation in patients with active ulcerative colitis
ECCO'20 Vienna
2020